Ruboxistaurin mesylate

Modify Date: 2024-01-01 18:35:10

Ruboxistaurin mesylate Structure
Ruboxistaurin mesylate structure
Common Name Ruboxistaurin mesylate
CAS Number 192050-59-2 Molecular Weight 564.65300
Density N/A Boiling Point N/A
Molecular Formula C29H32N4O6S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Ruboxistaurin mesylate


Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes[1][2][3][4].

 Names

Name Ruboxistaurin mesilate
Synonym More Synonyms

 Ruboxistaurin mesylate Biological Activity

Description Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes[1][2][3][4].
Related Catalog
Target

PKC-βI:4.7 nM (IC50)

PKC-βII:5.9 nM (IC50)

PKCη:52 nM (IC50)

PKCδ:250 nM (IC50)

PKCγ:300 nM (IC50)

PKCα:360 nM (IC50)

PKCε:600 nM (IC50)

In Vitro Ruboxistaurin mesylate 对 PKCα,PKCβI,PKCβII,PKCγ,PKCδ,PKCε 和 PKCη 的 IC50 值分别为 0.36,0.0047,0.0059,0.30,0.25,0.60 和 0.052 μM[1]。 Ruboxistaurin mesylate 抑制 Ca calmodulin 和大鼠脑 PKC 的 IC50 分别为 6.2 和 0.32 μM[1]。 Ruboxistaurin mesylate (10 和 400 nM;4 天) 显著抑制正常血糖 (NG) 条件下葡萄糖诱导的单核细胞粘附[3]。
In Vivo Ruboxistaurin mesylate (0.1, 1.0 和 10.0 mg/kg;口服,每日 1 次,共 3 周) 抑制糖尿病早期视网膜微循环中白细胞滞留的增加[4]。 Animal Model: Male long-evans rats with streptozotocin induced diabetes[4] Dosage: 0.1, 1.0 and 10.0 mg/kg Administration: Oral administration; 0.1, 1.0 and 10.0 mg/kg, once daily for 4 weeks Result: Significantly decreased the number of leukocytes in the retinal microcirculation of rats with streptozotocin induced diabetes.
References

[1]. Jirousek MR, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39(14):2664-2671.  

[2]. Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-199.  

[3]. Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1(6):929-35.  

[4]. Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2702-6.  

 Chemical & Physical Properties

Molecular Formula C29H32N4O6S
Molecular Weight 564.65300
Exact Mass 564.20400
PSA 134.74000
LogP 4.37440

 Synonyms

9-((Dimethylamino)methyl)-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo(E,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione,methanesulfonate,(9S)
13-((DIMETHYLAMINO)METHYL)-10,11,14,15-TETRAHYDRO-4,9:16,21-DIMETHENO-1H,13H-DIBENZO(E,K)PYRROLO(3,4-H)(1,4,13) OXADIAZACYCLOHEXADECENE-1,3(2H)-DIONE METHANESULFONATE
Ruboxistaurin mesylate
(S)-9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-dimethenodibenzo(e,k)pyrrolo(3,4h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione mesylate
UNII-6V860VW8AO